Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003920 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Cyclosporine inhibition of angiogenesis involves the transcription factor HESR1.
J Surg Res
October 2008
Department of Surgery, SUNY Upstate Medical University, Syracuse, New York 13210, USA.
Purpose: Angiogenesis is critical in normal development and in tumor growth. Experimentally, cyclosporine A (CyA) inhibits angiogenesis in an in vivo mouse model and an in vitro capillary tube model. The mechanisms behind its antiangiogenic effects are not well characterized.
View Article and Find Full Text PDFThe aim of the study was to disclose a possible association of hearing defects with the use of either cyclosporin (CyA) or tacrolimus (FK-506) in patients undergoing liver transplantation (LT). Pure-tone audiometry (PTA) was performed in the same 42 patients before and after LT. Audiometric frequencies recorded ranged from 250 to 8000 Hz.
View Article and Find Full Text PDFIncrease in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: a study in patients with stable renal allograft function.
Int J Clin Pharmacol Ther
September 2006
Clinic and Policlinic for Internal Medicine II - Nephrology, University of Regensburg, Regensburg, Germany.
Purpose: Acute effects of drug administration on renal arterial resistance index (RI) are still discussed controversially. In our study we investigated the immediate effects of cyclosporin A (CyA) and tacrolimus (FK-506) on renal arterial resistance indices in patients with stable graft function after renal transplantation. Additionally we studied the effects of nitroglycerin spray on resistance indices.
View Article and Find Full Text PDFSlowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial.
Transplantation
April 2006
Transplantation Center, University of Luebeck, School of Medicine, Germany.
Article Synopsis
- The study investigates whether switching kidney transplant recipients (KTR) from cyclosporine A (CyA) to tacrolimus (Tac) can slow down chronic allograft nephropathy (CAN) progression.
- After a year, the Tac group showed decreased serum creatinine levels and lower antihypertensive scores compared to the CyA group, indicating improved kidney function and lower blood pressure.
- The findings suggest that using Tac instead of CyA can lead to better long-term health outcomes for kidney transplants by potentially enhancing graft survival.
[A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
Ceska Slov Farm
November 2003
Ustav klinické biochemie a patobiochemie 2. LF UK a FN, Praha.
Cyclosporine A (CyA), tacrolimus (FK 506), and mycophenolic acid are routinely utilised immunosuppressive drugs used in the prevention of allograft rejection and the treatment of several autoimmune diseases. The monitoring of CyA blood levels plays the most important role to individualize the dosage regiment and to minimize acute rejection risk and drug toxicity. Inadequate low CyA doses and levels may result in the rejection of transplanted organs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!